Pharmaceutical companies flock to Hong Kong for listing, leading enterprises accelerate their overseas expansion and seek opportunities.

This year, 15 biopharmaceutical and medical health industry-related companies have successfully listed on the Hong Kong Stock Exchange, with 36 more companies in the same industry submitting prospectuses to the exchange. According to research reports by Dongwu Securities, the pharmaceutical industry is a typical innovation-driven industry and the source of sector growth lies in innovation. The development of innovative drugs in China has gone through a difficult transformation from imitation to innovation, and the innovative drug industry has reached a turning point.